Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2023-01-11 00:00:00 ET · period of report 2023-01-10 · accession 0001209191-23-002979 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-11 | 2023-01-10 | FATE | Wolchko J Scott | Pres, CEO, Dir | S - Sale | $5.24 | -45.9K | 385.6K | -11% | -$240.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-10 | S | D | 45,907 | $5.24 | 385,639 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $5.11 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |